22 Apr

What Are Analysts Recommending for Johnson & Johnson?

WRITTEN BY Margaret Patrick

Stock price movements

On April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its 52-week low of $118.62, and 7.03% lower than its 52-week high of $148.99.

The company’s market cap was $370.98 billion, and its PE, forward PE, price-to-sales, price-to-book, and price-to-cash multiples were 24.69x, 15.17x, 4.55x, 6.21x, and 18.84x, respectively.

What Are Analysts Recommending for Johnson & Johnson?

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Analysts’ recommendations and target prices

Wall Street analysts expect an upside potential of 6.30% for Johnson & Johnson based on the company’s closing price on April 17. Analysts first raised the company’s 12-month consensus target price from $144.22 in February to $144.71 in March and then to $147.24 in April. The current consensus analyst recommendation for the stock is a “buy.”

Of the 19 analysts covering Johnson & Johnson, four have given the stock “strong buy” recommendations, six have given it “buys,” eight have given it “holds,” and only one has given it a “sell.”

Segmental performance

In the first quarter, the company’s Consumer segment reported revenue of $3.32 billion, a YoY (year-over-year) fall of 2.4% on a reported basis. However, its revenue was up 2.2% YoY on an operational basis and 0.7% YoY on an adjusted operational basis. According to the company’s first-quarter earnings conference call, this performance was associated with its increasing share in the over-the-counter medicines market, the return of the Tylenol brand to a leading position in the analgesics market, and the robust uptake of Neutrogena and OGX in the beauty market.

In the first quarter, JNJ’s Pharmaceutical segment reported revenue of $10.24 billion, reflecting YoY rises of 4.1% on a reported basis and 7.9% on an operational and adjusted operational basis. According to the company’s first-quarter earnings conference call, this performance was driven by double-digit revenue growth in nine key products.

In the first quarter, the company’s Medical Devices segment reported revenue of $6.46 billion, reflecting YoY rises of 0.1% on a reported basis, 3.9% on an operational basis, and 5.5% on an adjusted operational basis. According to the company’s first-quarter earnings conference call, this performance was driven by robust performances in the vision, interventional solutions, and advanced surgery categories.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.

172.31.38.64